Analyst Ratings For Clovis Oncology (NASDAQ:CLVS)

.

Some recent analyst ratings include

• 2/27/2018-Cann Reiterated Rating of Hold.
• 2/22/2018-Evercore ISI Upgrade from a “In-Line ” rating to a ” Outperform” rating.
• 2/22/2018-Royal Bank of Canada Upgrade from a “Sector Perform ” rating to a ” Outperform” rating.
• 1/11/2018-JPMorgan Chase & Co. Reiterated Rating of Buy.
• 12/20/2017-Oppenheimer Reiterated Rating of Hold.

• On 2/22/2018 Thorlef Spickschen, Director, sold 4,500 with an average share price of $60.00 per share and the total transaction amounting to $270,000.00.
• On 2/15/2018 Gillian C Ivers-Read, Insider, sold 3,000 with an average share price of $54.09 per share and the total transaction amounting to $162,270.00.
• On 1/16/2018 Gillian C Ivers-Read, Insider, sold 3,000 with an average share price of $59.16 per share and the total transaction amounting to $177,480.00.
• On 1/8/2018 Thorlef Spickschen, Director, sold 4,500 with an average share price of $64.97 per share and the total transaction amounting to $292,365.00.
• On 12/15/2017 Gillian C Ivers-Read, Insider, sold 3,000 with an average share price of $64.16 per share and the total transaction amounting to $192,480.00.
• On 12/8/2017 Thorlef Spickschen, Director, sold 4,500 with an average share price of $60.00 per share and the total transaction amounting to $270,000.00.
• On 11/15/2017 Gillian C Ivers-Read, Insider, sold 3,000 with an average share price of $63.70 per share and the total transaction amounting to $191,100.00.

Recent Trading Activity for Clovis Oncology (NASDAQ:CLVS)
Shares of Clovis Oncology closed the previous trading session at 59.11 up +3.60 6.49% with shares trading hands.